New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
June 19, 2021 18:30 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly...
Core One Labs Retains Canada’s Highest-Ranked IP Law Firm to Assist With Patent Filings
June 18, 2021 03:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 18, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce it has retained...
Core One Labs Plans Share Consolidation in Preparation of Listing its Common Shares on Nasdaq
June 16, 2021 03:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) advises that in preparation...
REPEAT - Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
June 14, 2021 09:15 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its...
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
June 12, 2021 18:39 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, June 12, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its...
REPEAT – Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
May 06, 2021 09:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
May 06, 2021 03:10 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that...
REPEAT - World Renowned Physician Joins Core One Labs as Chief Medical Officer
May 05, 2021 09:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has...
World Renowned Physician Joins Core One Labs as Chief Medical Officer
May 05, 2021 03:10 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has...
REPEAT - Core One Labs Completes Milestone Acquisition of Akome Biotech
May 04, 2021 09:00 ET
|
Core One Labs Inc.
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and...